Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Osimertinib

FLAME: osimertinib plus chemotherapy in persistent ctDNA EGFR-mutant NSCLC
1:15
FLAME: osimertinib plus chemotherapy in persistent ctDNA EGFR-mutant NSCLC
Erika Ruiz-Garcia • 3 Jun 2026
Tepotinib in MET-amplified NSCLC: real-world outcomes from Australia
3:23
Tepotinib in MET-amplified NSCLC: real-world outcomes from Australia
Surein Arulananda • 11 Dec 2025
Elucidating the novel standard of care for EGFR-positive lung cancer
1:52
Elucidating the novel standard of care for EGFR-positive lung cancer
Sanjay Popat • 13 Nov 2025
Systemic therapy options for patients with NSCLC who relapse
2:45
Systemic therapy options for patients with NSCLC who relapse
Sanjay Popat • 13 Nov 2025
Refining treatment strategies in EGFR-mutant NSCLC
1:21
Refining treatment strategies in EGFR-mutant NSCLC
Martin Schuler • 10 Nov 2025
Treating patients with NSCLC who relapse on osimertinib-based therapies
1:19
Treating patients with NSCLC who relapse on osimertinib-based therapies
Sanjay Popat • 17 Sep 2025
MARIPOSA: resistance mechanisms of amivantamab & lazertinib in NSCLC
3:12
MARIPOSA: resistance mechanisms of amivantamab & lazertinib in NSCLC
Sanjay Popat • 17 Sep 2025
Evaluating the future role of tegavivint and osimertinib in EGFRm NSCLC
0:56
Evaluating the future role of tegavivint and osimertinib in EGFRm NSCLC
Regan Memmott • 12 Sep 2025
How might tegavivint complement EGFR inhibition in lung cancer?
0:53
How might tegavivint complement EGFR inhibition in lung cancer?
Regan Memmott • 12 Sep 2025
Osimertinib and chemotherapy as the standard of care in EGFRm NSCLC
1:40
Osimertinib and chemotherapy as the standard of care in EGFRm NSCLC
Samreen Ahmed • 11 Sep 2025
FLAURA2 outcomes by EGFR mutation subtype in advanced NSCLC
1:34
FLAURA2 outcomes by EGFR mutation subtype in advanced NSCLC
Samreen Ahmed • 11 Sep 2025
CHRYSALIS-2: MET IHC as a biomarker for amivantamab-lazertinib in NSCLC
2:47
CHRYSALIS-2: MET IHC as a biomarker for amivantamab-lazertinib in NSCLC
Benjamin Besse • 9 Sep 2025
Updates in EGFRm NSCLC at WCLC 2025: FLAURA2, ACROSS 2 & HARMONi
2:03
Updates in EGFRm NSCLC at WCLC 2025: FLAURA2, ACROSS 2 & HARMONi
Alessio Cortellini • 8 Sep 2025
Safety of osimertinib plus tegavivint in first-line EGFR-mutant NSCLC
2:17
Safety of osimertinib plus tegavivint in first-line EGFR-mutant NSCLC
Regan Memmott • 8 Sep 2025
Real-world outcomes of 2L carboplatin and pemetrexed in EGFRm NSCLC
0:56
Real-world outcomes of 2L carboplatin and pemetrexed in EGFRm NSCLC
Igor Gómez-Randulfe • 7 Sep 2025
Identifying cause of disparities in NSCLC outcomes
3:34
Identifying cause of disparities in NSCLC outcomes
Raymond Osarogiagbon • 17 Jul 2025
The content of VJOncology is intended for healthcare professionals